Physician profile
Yi Wang
NPI 1427248319
$14,341.06
in general payments reported to CMS, 2019-2025
46 companies · $1,552 in 2025
The $1,552 reported for 2025 was more than what 95% of Geriatric Medicine (Family Medicine) providers received nationally (typical 2025 total: $119).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,276 · 2020: $1,763 · 2021: $2,649 · 2022: $1,743 · 2023: $2,324 · 2024: $2,034 · 2025: $1,552.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,890 · Education: $20.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,890.45 |
| Education | $20.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $1,434.21 | 2019-2025 | Farxiga, Airsupra, Andexxa |
| Amgen INC. | $1,347.33 | 2019-2025 | Evenity, Prolia, Repatha |
| Lilly USA, LLC | $1,235.44 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Novo Nordisk INC | $1,147.55 | 2019-2025 | Rybelsus, Ozempic |
| Janssen Pharmaceuticals, INC | $916.00 | 2019-2022 | |
| Glaxosmithkline, LLC. | $781.51 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Bayer Healthcare Pharmaceuticals INC. | $748.24 | 2022-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $679.93 | 2019-2025 | Jardiance |
| Astellas Pharma US INC | $618.03 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $576.31 | 2019-2025 | |
| Radius Health, INC. | $524.14 | 2019-2025 | Tymlos |
| Kowa Pharmaceuticals America, INC. | $431.45 | 2019-2025 | Livalo, Seglentis, Zoryve |
| Merck Sharp & Dohme LLC | $346.03 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $342.88 | 2019-2025 | Xifaxan |
| Amarin Pharma, INC. | $314.96 | 2019-2021 |
Show all 46 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironwood Pharmaceuticals, INC | $289.76 | 2019-2024 | Linzess |
| Esperion Therapeutics, INC. | $244.73 | 2021-2025 | Nexletol |
| Pfizer INC. | $234.71 | 2019-2024 | |
| Scilex Pharmaceuticals INC. | $229.97 | 2019-2024 | Ztlido |
| Allergan, INC. | $226.71 | 2019-2020 | |
| Sumitomo Pharma America, INC. | $220.78 | 2023-2025 | Gemtesa |
| Abbvie INC. | $167.07 | 2021-2023 | Linzess, Creon, Viberzi |
| Exact Sciences Corporation | $137.53 | 2024-2025 | Cologuard Collection Kit |
| Redhill Biopharma INC. | $127.93 | 2022-2024 | Talicia |
| Sanofi-Aventis U.S. LLC | $123.41 | 2019-2022 | |
| Nestle Healthcare Nutrition INC. | $111.38 | 2021-2023 | |
| Bioventus LLC | $96.11 | 2019-2020 | |
| Mannkind Corporation | $94.88 | 2020 | |
| Sunovion Pharmaceuticals INC. | $85.16 | 2019-2022 | |
| Otsuka America Pharmaceutical, INC. | $58.69 | 2023-2025 | Rexulti |
| Aimmune Therapeutics, INC. | $53.76 | 2024-2025 | Zenpep |
| Vivus LLC | $45.35 | 2022-2023 | Pancreaze |
| Takeda Pharmaceuticals U.S.A., INC. | $42.03 | 2019 | |
| Xeris Pharmaceuticals, INC. | $40.87 | 2021-2023 | Gvoke Hypopen |
| Phathom Pharmaceuticals, INC. | $35.86 | 2024 | Voquezna |
| Corium, LLC | $30.27 | 2023 | Adlarity |
| Alvogen INC | $27.13 | 2023 | Teriparatide |
| Almatica Pharma LLC | $25.43 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $24.83 | 2019 | |
| Medicure Pharma INC. | $22.91 | 2022 | |
| Eisai INC. | $19.66 | 2022 | |
| Depuy Synthes Sales INC. | $19.25 | 2019 | |
| Biogen, INC. | $17.70 | 2021 | |
| Arbor Pharmaceuticals, INC. | $15.49 | 2020 | |
| Zimmer Biomet Holdings, INC. | $14.93 | 2025 | Gel-One Cross-Linked Hyaluronate |
| E.R. Squibb & Sons, L.L.C. | $12.76 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yi Wang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.